Skip to Content

Is dopamine reward from drugs stronger than natural rewards?

Dopamine is a neurotransmitter that plays a major role in reward and pleasure. It is released when we experience things that make us feel good, such as eating, sex, and social interactions. Drugs like cocaine, amphetamines, nicotine, and alcohol cause a large release of dopamine in the brain’s reward system, which creates a euphoric high or buzz. This leads to the classic question: is the dopamine hit and feeling of reward stronger from drugs compared to natural rewards?

The Role of Dopamine in Reward

Dopamine is often portrayed as the “pleasure chemical” or “reward molecule” in the brain. But more accurately, dopamine signals reward prediction and incentive salience – how much we want something and how motivated we are to seek it out. When dopamine is released in the reward system of the brain (particularly the nucleus accumbens), it helps flag rewarding behaviors as important and reinforces us to repeat them.

Natural rewards like food, sex, and social bonding cause dopamine release because our brains have evolved to find these things pleasurable and essential for survival. Drugs of abuse piggyback on this dopamine reward pathway. They flood the system with much higher levels of dopamine than natural rewards, which produces euphoria, intense pleasure, and strong reinforcement to take the drug again.

Animal studies found that mice will forego food, water, sex, and social interaction to continue pressing a lever for cocaine. The cocaine hijacks the reward pathway more powerfully than behaviors needed for survival. Human drug addicts often neglect responsibilities, relationships, and health in favor of seeking drugs, highlighting their highly addictive nature.

Measuring Dopamine Release

Neuroimaging techniques like PET scans have allowed researchers to compare dopamine release between natural rewards and addictive drugs in humans. In normal individuals, dopamine release was highest for methamphetamine, second highest for cocaine, and lower for natural reinforcers like food and sex.

One study found dopamine increases of up to 700% for methamphetamine, 250-300% for cocaine, and 50-100% for natural rewards. So drugs cause much greater surges of dopamine compared to what the brain experiences naturally. Similar to the animal research, this demonstrates the power of drugs above survival drives.

Addictiveness of Different Drugs

The addictiveness and dopamine effect differs somewhat between drug classes:

  • Stimulants like cocaine, methamphetamine, nicotine, and caffeine cause strong dopamine spikes and pleasurable highs, reinforcing addictive patterns.
  • Opiates like heroin, morphine, and oxycodone produce euphoria through opioid receptors, with dopamine likely playing an amplifying role.
  • Psychedelics like LSD and psilocybin (‘shrooms) mainly act on serotonin receptors and are not physically addictive, though users can develop psychological dependence.
  • Alcohol increases dopamine and GABA neurotransmitters, creating euphoric and sedative effects. While addictive, the dopamine effect is weaker than for stimulants.

The rapid dopamine rushes from stimulants like meth and cocaine make them the most acutely addictive and likely to be abused. Opiates, alcohol, nicotine, and certain prescription drugs can also hijack reward pathways and produce strong addictions over time.

Natural vs Drug Rewards Over Time

Research in rats suggests that over time and repeated exposure, the dopamine response can decrease more rapidly for drug rewards versus natural rewards. This may contribute to drug tolerance and the need for escalating use.

In one study, rats pressed levers to self-administer either sugar water (a natural reinforcer) or cocaine. Over sessions spanning 15 days, the dopamine response declined faster for cocaine compared to sugar. Rats had to increase cocaine intake to try to achieve the same dopamine effects.

The researchers proposed this reflects the difference between drugs as “superphysiological reinforcers” compared to food and other natural rewards that produced more sustainable dopamine levels. However, human studies have not consistently replicated faster tolerance to drug rewards.

Conditioned Responses

While the dopamine spike may be larger for drug use, natural rewards can produce considerable dopamine release too, especially for new experiences. Dopamine surges for natural rewards can also be amplified by conditioned responses.

If a cue or environment becomes associated with something pleasurable, like eating your favorite food, seeing the cue alone can trigger dopamine release in anticipation. This is why food cues, locations related to drug use, and even the sight of drug paraphernalia can trigger cravings and dopamine.

So dopamine firing depends not just on the size of the potential reward, but learning processes and conditioned anticipatory responses. This may help explain why food cravings can also feel extremely intense.

Individual Differences

While on average recreational drugs release more dopamine than natural rewards, there are individual differences in dopamine receptor availability and reward sensitivity that influence this:

  • People with lower dopamine receptor availability may be more likely to derive extreme pleasure and reinforcement from initial drug use.
  • People with certain gene variants affecting dopamine transmission have enhanced reward reactions to both drug and natural reinforcers.
  • Individuals prone to addiction are more sensitive to dopamine effects. For them, natural rewards may produce higher dopamine release than for non-addicted individuals.
  • Women on average have higher dopamine release from addictive drugs compared to men, which may contribute to sex differences in addiction vulnerability.

In vulnerable individuals, then, some natural rewards may produce hedonic effects and dopamine surges approaching levels from drug use. This blend of genetic and environmental factors helps explain why only a subset of people go on to develop drug addictions.

Downregulation and Dysfunction

While initially drugs cause greater dopamine spikes, chronic use leads to changes in the brain that reduce reward sensitivity. This involves downregulation and desensitization of dopamine receptors. One PET study found participants dependent on amphetamines, cocaine, and alcohol all showed markedly lower dopamine receptor levels compared to non-addicts.

This blunting of the dopamine system makes the person less responsive to everyday pleasures and natural reinforcers. Seeking the larger dopamine rush from drugs becomes a way to compensate for this reward deficit. But drug use further disrupts and imbalances dopamine neurotransmission, fueling addiction behaviors.

Anhedonia and Drug Withdrawal

When people with addiction stop using drugs, they face anhedonia – the inability to feel pleasure – and depression. During withdrawal, the dopamine system remains dysfunctional and natural rewards have trouble competing with the now established drug-seeking habits.

This helps explain why drug cravings and relapse remain a major challenge even after detox. With sustained abstinence, however, dopamine receptors can regrow and reward sensitivity recovers. But the length of this dopamine recovery process varies individually and by drug class.


In summary, while addictive drugs produce larger spikes of dopamine than natural reinforcers, this reflects an artificial hijacking of reward pathways. The dopamine system did not evolve to handle the supraphysiological effects of drugs. Over time, drug use leads to dysfunction and numbing of dopamine pathways involved in everyday pleasure and motivation. The outsized dopamine effects also reinforce compulsive drug-seeking that is difficult to shake.

For individuals vulnerable to addiction, dopamine release from some natural rewards may approach levels seen with drugs. And drug-related cues can amplify dopamine based on conditioned learning. This demonstrates that the dopamine system, while usurped by drugs in the short-term, remains optimized for adaptive rewards needed for survival and wellbeing. Targeting dopamine dysfunction represents an important direction for treating addiction.


Baumeister, D., Wolf, I., Holz, N., Boecker, R., Adam, R., Sprenger, A., … & Holtmann, M. (2015). Neurofeedback training effects on inhibitory brain activation in ADHD: A matter of learning?. Neuroscience, 367, 89-99.

Berridge, K. C., & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist, 71(8), 670.

Blum, K., Liu, Y., Shriner, R., & Gold, M. S. (2011). Reward circuitry dopaminergic activation regulates food and drug craving behavior. Current pharmaceutical design, 17(12), 1158-1167.

Bough, K. J., & Rho, J. M. (2013). Anticonvulsant mechanisms of the ketogenic diet. Epilepsia, 8(1), 223–232.

Di Chiara, G., & Bassareo, V. (2007). Reward system and addiction: what dopamine does and doesn’t do. Current opinion in pharmacology, 7(1), 69-76.

Diana, M. (2011). The dopamine hypothesis of drug addiction and its potential therapeutic value. Frontiers in psychiatry, 2, 64.

Elman, I., Karlsgodt, K. H., & Gastfriend, D. R. (2001). Gender differences in cocaine craving among non-treatment-seeking individuals with cocaine dependence. The American journal of drug and alcohol abuse, 27(2), 193-202.

Everitt, B. J., & Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature neuroscience, 8(11), 1481-1489.

Flagel, S. B., Clark, J. J., Robinson, T. E., Mayo, L., Czuj, A., Willuhn, I., … & Akil, H. (2011). A selective role for dopamine in stimulus-reward learning. Nature, 469(7328), 53-57.

Garavan, H., Pankiewicz, J., Bloom, A., Cho, J. K., Sperry, L., Ross, T. J., … & Stein, E. A. (2000). Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. American Journal of Psychiatry, 157(11), 1789-1798.

Giuliano, C., Robbins, T. W., Nathan, P. J., Bullmore, E. T., & Everitt, B. J. (2012). Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating. Neuropsychopharmacology, 37(12), 2643-2652.

Goldstein, R. Z., & Volkow, N. D. (2011). Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nature reviews neuroscience, 12(11), 652-669.

Heilig, M., Epstein, D. H., Nader, M. A., & Shaham, Y. (2016). Time to connect: bringing social context into addiction neuroscience. Nature Reviews Neuroscience, 17(9), 592-599.

Karila, L., Weinstein, A., Aubin, H. J., Benyamina, A., Reynaud, M., & Batki, S. L. (2010). Pharmacological approaches to methamphetamine dependence: a focused review. British journal of clinical pharmacology, 69(6), 578-592.

Keiflin, R., & Janak, P. H. (2015). Dopamine prediction errors in reward learning and addiction: from theory to neural circuitry. Neuron, 88(2), 247-263.

Leyton, M., & Vezina, P. (2013). Striatal ups and downs: their roles in vulnerability to addictions in humans. Neuroscience & Biobehavioral Reviews, 37(9), 1999-2014.

Lüscher, C., & Malenka, R. C. (2011). Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron, 69(4), 650-663.

McLellan, A. T., Lewis, D. C., O’brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. Jama, 284(13), 1689-1695.

Nestler, E. J. (2005). Is there a common molecular pathway for addiction?. Nature neuroscience, 8(11), 1445-1449.

Perry, C. J., & Lawrence, A. J. (2017). Addiction, dopamine and the molecular mechanisms of memory. In The Neurobiological Basis of Memory (pp. 431-464). Springer, Cham.

Schultz W. (2015). Neuronal Reward and Decision Signals: From Theories to Data. Physiological reviews, 95(3), 853–951.

Sinha, R. (2008). Chronic stress, drug use, and vulnerability to addiction. Annals of the new York Academy of Sciences, 1141, 105.

Sorge, R. E., Rajabi, H., & Stewart, J. (2005). Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement. Neuropsychopharmacology, 30(9), 1681-1692.

Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D., & Telang, F. (2011). Addiction: beyond dopamine reward circuitry. Proceedings of the National Academy of Sciences, 108(37), 15037-15042.

Wise, R. A., & Rompre, P. P. (1989). Brain dopamine and reward. Annual review of psychology, 40(1), 191-225.